Vevye®
cyclosporine ophthalmic solution 0.1%
Clinical Snapshot
Vevye is a water-free, perfluorocarbon-based cyclosporine formulation providing the highest commercially available cyclosporine concentration (0.1%) in a novel vehicle designed to improve tolerability and corneal penetration.
Mechanism of Action
Cyclosporine inhibits calcineurin, reducing T-cell activation and pro-inflammatory cytokine release. The perfluorocarbon vehicle enhances corneal penetration and tolerability compared to earlier emulsion-based formulations.
Common Clinical Applications
- Signs and symptoms of dry eye disease
Typical Dosing Principles
One drop in each eye twice daily. The water-free vehicle is designed to improve comfort and reduce burning.
Dosing information is provided for educational purposes. Always consult current prescribing information for specific dosing protocols.
Important Precautions
- Contraindicated in patients with active ocular infections.
- Patients should remove contact lenses prior to instillation and may reinsert 15 minutes after dosing.
Clinical Pearls
- The perfluorocarbon vehicle offers a distinct tolerability profile — a useful option for patients who discontinued earlier cyclosporine formulations due to burning.
- Onset of clinical effect is gradual; patients benefit from realistic expectations.
- Consider in patients with significant corneal staining or goblet cell loss.
Commonly Associated Disease States
Select any disease state to explore its full entry in the Disease State Library.
This entry is an educational reference designed to support clinical reasoning and therapeutic awareness. It does not constitute medical advice, establish a standard of care, or replace individualized patient assessment. Clinicians should consult current prescribing information before initiating any therapy.